Ayşe Nur Bayındır Akbaş

Ayşe Nur Bayındır Akbaş

Auto-generated profile, based on publicly available information

Ayşe Nur Bayındır Akbaş

Department of Rheumatology, Denizli State Hospital, Denizli, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TOTuğba OCAK
Tuğba OCAK
BYBurcu Yagiz
Burcu Yagiz
BOBirol Ocak
Birol Ocak
ÖYÖzge Yoğurtçu
Özge Yoğurtçu
FBFatma Başıbüyük
Fatma Başıbüyük
YPYavuz Pehlivan
Yavuz Pehlivan
Background: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug’s survival time and the efficacy and safety of secukinumab treatment in this specific patient group. Methods: This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA. Results: The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder. Conclusions: In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.

Verified
Journal Article
Open access
PDF file
TOTuğba OCAK
Tuğba OCAK
BYBurcu Yagiz
Burcu Yagiz
BCBelkis Nihan Coşkun
Belkis Nihan Coşkun
GAGamze Akkuzu
Gamze Akkuzu
AAAyşe Nur Bayındır Akbaş
Ayşe Nur Bayındır Akbaş
YPYavuz Pehlivan
Yavuz Pehlivan
Background: Secukinumab is a fully human monoclonal antibody that targets interleukin (IL)-17A and is used to treat axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Treating axSpA and PsA can be challenging in patients with comorbidities. In this multicenter retrospective study, we aimed to evaluate the efficacy and safety of secukinumab treatment in patients with axSpA and PsA who had a history of tuberculosis, multiple sclerosis (MS), or congestive heart failure (CHF). Methods: The study included 44 patients with a diagnosis of axSpA and PsA and a history of tuberculosis, MS, or CHF who received secukinumab treatment at 13 centers in our country. Erythrocyte sedimentation rate, C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score CRP, visual analog scale, and Disease Activity Score-28 CRP markers at months 0, 3, and 12 of secukinumab treatment were analyzed. Alongside this, tuberculosis, MS, and CHF were evaluated at follow-up using clinical assessments and imaging methods such as chest radiographs, brain magnetic resonance, and echocardiography. Results: A statistically significant improvement in inflammatory markers and disease activity scores was observed in patients treated with secukinumab. There was no reactivation in patients with a history of tuberculosis. In most MS patients, the disease was stable, while clinical and radiological improvement was observed in one patient. No worsening of CHF stage was observed in patients with a history of CHF. Conclusions: With regular clinical monitoring, secukinumab may be an effective and safe treatment option for axSpA and PsA patients with a history of tuberculosis, MS, or CHF.

20 August 2026 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
MBMA Balcı
MA Balcı
ZYZ Yağbasan
Z Yağbasan
IGİ Gunduz
İ Gunduz
AAAN Bayindir Akbaş
AN Bayindir Akbaş
FAFatih Albayrak
Fatih Albayrak
GCGozde Yildirim Cetin
Gozde Yildirim Cetin
Systemic sclerosis (SSc), also known as scleroderma, is a rare and complex autoimmune connective tissue disease. It is characterized by progressive fibrosis, vascular abnormalities, and severe comp...

23 September 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
EKElif Gur Kabul
Elif Gur Kabul
SBSinem Bozcuk
Sinem Bozcuk
BCBilge Basakci Calik
Bilge Basakci Calik
AAAyse Nur Bayındır Akbas
Ayse Nur Bayındır Akbas
VCVeli Cobankara
Veli Cobankara

2 April 2026 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Closed access
ZGZeynep Ilknur Pt Genc
Zeynep Ilknur Pt Genc
BCBilge Basakci Calik
Bilge Basakci Calik
EKElif Gur Kabul
Elif Gur Kabul
SBSinem Pt Bozcuk
Sinem Pt Bozcuk
AAAyşe Nur MD Bayindir Akbas
Ayşe Nur MD Bayindir Akbas
VCVeli Cobankara
Veli Cobankara
Objective: The aim was to investigate the factors affecting and associated with work performance of rheumatoid arthritis (RA) patients. Methods: Fifty RA were included. Results: The average annual disease leave was 4.16±8.77 days. 12% of patients changed works due to disease, 32% reduced working hours, 20% quit works. Arthritis Work Spillover Scale had low correlation with Disease Activity Score-28, ABILHAND-RA questionnaire, Biopsychosocial Questionnaire, St. George's Respiratory Questionnaire-Activity, Short Form-36-Mental, Unsupported Upper-Limb Exercise Test-duration and level, maximal inspiratory pressure, maximal expiratory pressure (r:0.282-r:0.453) and had moderate correlation with Visual Analog Scale-General Pain, Health Assessment Questionnaire, Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), DASH-W, Short Form-36-Physical (r:0.516-r:-0.687)(p<0.05). Conclusions: With significant impact on working life, work spillover related to disease activity, pain, functionality, respiratory muscle strength, biopsychosocial status, respiratory and health-related quality of life in RA. Export

31 August 2023 in Turkish Journal of Diabetes and Obesity
Verified
Journal Article
Open access
PDF file
EKElif Gur Kabul
Elif Gur Kabul
BABegüm Akar
Begüm Akar
BÇBilge Başakçi Çalik
Bilge Başakçi Çalik
AAAyşe Nur BAYINDIR AKBAŞ
Ayşe Nur BAYINDIR AKBAŞ
VÇVeli Çobankara
Veli Çobankara
Aim: The aim of this study was to investigate the body composition and dietary habits of patients with Rheumatoid Arthritis (RA) and to compare them with healthy controls. Material and Methods: 64 participants (RA n=32 and mean age: 55.2±1.5 years; Healthy Group n=32 and mean age: 54.5±1.5 years) were included in the study. Body compositions (body mass index, body fat ratio, skeletal muscle mass, skeletal muscle mass index) were evaluated with the body analysis system device (Polosmart PSC12 Prolife) and dietary habits (meat/fish consumption, legumes consumption, egg consumption, milk/dairy product consumption and liquid consumption) were evaluated with questions created by the researchers. In the comparison of independent group differences, the Independent Samples T Test was used when the parametric test assumptions were met, and the Mann Whitney U test was used when the parametric test assumptions were not met.. Results: When comparing body compositions, there was a significant difference in skeletal muscle mass (p=0.001) and skeletal muscle mass index (p=0.002) in favor of the healthy group; but body mass index and body fat ratios were similar (p>0.05). When comparing the dietary habits, milk/dairy product (p=0.008), meat/fish (p=0.001), legumes (p=0.001) and liquid (p=0.046) consumptions were higher in healthy group; but egg consumption was similar (p>0.05) Conclusion: The patients with RA had less muscle mass, lower skeletal muscle mass index scores, and worse nutritional levels compared to healthy controls. In the light of these results, we recommend that patients with RA receive support from professional centers regulating dietary habits, as well as exercise methods that increase muscle mass.